FDA Approves Another Drug for Treating Acute Infections

Orbactiv is approved for treating patients with MRSA and some other bacteria.

The U.S. Food and Drug Administration approved Orbactiv (oritavancin), a new antibacterial drug to treat adults with acute bacterial skin infections, including Staphylococcus aureus (both methicillin-susceptible and methicillin-resistant strains), various Streptococcus species, and Enterococcus faecalis, on Aug. 6. The drug is administered intravenously. It is marketed by The Medicines Company, based in Parsippany, N.J.

Orbactiv is the third new antibacterial drug FDA has approved this year to treat such infections; the others are Dalvance (dalbavancin) and Sivextro (tedizolid). "The approval of several new antibacterial drugs this year demonstrates that we are making progress in increasing the availability of treatment options for patients and physicians," said Dr. Edward Cox, M.D., MPH, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research. "However, more work is needed in this area, and the FDA remains a committed partner to help promote the development of antibacterial drugs."

Orbactiv also is the third new drug designated as a Qualified Infectious Disease Product to receive FDA approval. Under the Generating Antibiotic Incentives Now title of the FDA Safety and Innovation Act, Orbactiv was granted QIDP designation because it is an antibacterial or antifungal human drug intended to treat a serious or life-threatening infection.

According to FDA's news release, the most common side effects identified in clinical trials of the drug were headache, nausea, vomiting, the formation of skin and soft tissue abscesses on arms and legs, and diarrhea. Orbactiv's label includes a warning about interference with coagulation tests and interaction with warfarin, a drug that is used to prevent blood clots.

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • The Top 5 Safety and Technology Trends to Watch in 2019

    Get the latest on trends you can expect to hear more about in 2019, including continued growth of mobile safety applications, wearable technology, and smart PPE; autonomous vehicles; pending OSHA recordkeeping rulemaking; and increased adoption of international safety standard, ISO 45001.

  • Get the Ultimate Guide to OSHA Recordkeeping

    OSHA’s Form 300A posting deadline is February 1! Are you prepared? To help answer your key recordkeeping questions, IndustrySafe put together this guide with critical compliance information.

  • Safety Training 101

    When it comes to safety training, no matter the industry, there are always questions regarding requirements and certifications. We’ve put together a guide on key safety training topics, requirements for certifications, and answers to common training questions.

  • Conduct EHS Inspections and Audits

    Record and manage your organization’s inspection data with IndustrySafe’s Inspections module. IndustrySafe’s pre-built forms and checklists may be used as is, or can be customized to better suit the needs of your organization.

  • Industry Safe

OH&S Digital Edition

  • OHS Magazine Digital Edition - January 2019

    January 2019

    Featuring:

    • PREVENTING ERRORS
      Production vs. Safety 
    • EMERGENCY SHOWERS & EYEWASH
      Meeting the Requirements for Emergency Equipment
    • CONSTRUCTION SAFETY
      The State of Contractor Safety
    • FOOT PROTECTION
      The Three Keys to Effective Chemical Management
    View This Issue